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Summary
The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) are 
coordinating a multi-state investigation of fungal meningitis among patients who received an epidural 
steroid injection. Several of these patients also suffered strokes that are believed to have resulted from 
their infection. As of October 4, 2012, five deaths have been reported. Fungal meningitis is not 
transmitted from person to person. These cases are associated with a potentially contaminated 
medication. Investigation into the exact source is ongoing; however, interim data show that all infected 
patients received injection with preservative-free methylprednisolone acetate (80mg/ml) prepared by New 
England Compounding Center, located in Framingham, MA.
Background
On September 21, 2012, CDC was notified by the Tennessee Department of Health of a patient with the 
onset of meningitis approximately 19 days following epidural steroid injection at a Tennessee ambulatory 
surgery center (ASC). Initial cultures of cerebrospinal fluid (CSF) and blood were negative; subsequently, 
Aspergillus fumigatus was isolated from CSF by fungal culture. On September 28, investigators identified 
a case outside of Tennessee, possibly indicating contamination of a widely distributed medication. As of 
October 4, a total of 35 cases* in the following six states have been identified with a clinical picture 
consistent with fungal infection: Florida (2 cases), Indiana (1 case), Tennessee (25 cases, including 3 
deaths), Maryland (2 cases, including 1 death), North Carolina (1 case), and Virginia (4 cases, including 1 
death). Fungus has been identified in specimens obtained from five patients, one of whom also had 
Propionobacterium acnes, of unclear clinical significance, isolated from a post-mortem central nervous 
system specimen.
Infected patients have presented approximately 1 to 4 weeks following their injection with a variety of 
symptoms, including fever, new or worsening headache, nausea, and new neurological deficit (consistent 
with deep brain stroke). Some of these patients’ symptoms were very mild in nature. CSF obtained from 
these patients has typically shown elevated white cell count (with a predominance of neutrophils), low 
glucose, and elevated protein.
Recommendations
On September 25, 2012, the New England Compounding Center located in Framingham, MA voluntarily 
recalled the following lots of methylprednisolone acetate (PF) 80mg/ml:
• Methylprednisolone Acetate (PF) 80 mg/ml Injection, Lot #05212012@68, BUD 11/17/2012
• Methylprednisolone Acetate (PF) 80 mg/ml Injection, Lot #06292012@26, BUD 12/26/2012
• Methylprednisolone Acetate (PF) 80 mg/ml Injection, Lot #08102012@51, BUD 2/6/2013
On October 3, 2012, the compounding center ceased all production and initiated recall of all 
methylprednisolone acetate and other drug products prepared for intrathecal administration.
Physicians should contact patients who have had an injection (e.g., spinal, joint) using any of the three 
lots of methylprednisolone acetate listed above to determine if they are having any symptoms. Although 
all cases detected to date occurred after injections with products from these three lots, out of an 
abundance of caution, CDC and FDA recommend that healthcare professionals cease use of any product 
produced by the New England Compounding Center until further information is available.
For patients who received epidural injection and have symptoms of meningitis or basilar stroke, a 
diagnostic lumbar puncture (LP) should be performed, if not contraindicated. Because presenting 
symptoms of some patients with meningitis have been mild and not classic for meningitis (e.g., new or 
worsening headache without fever or neck stiffness), physicians should have a low threshold for LP.
While CDC is aware of infections occurring only in patients who have received epidural steroid injections, 
patients who received other types of injection with methylprednisolone acetate from those three lots 
should also be contacted to assess for signs of infection (e.g., swelling, increasing pain, redness, warmth 
at the injection site) and should be encouraged to seek evaluation (e.g., arthrocentesis) if such symptoms 
exist.
For guidance on diagnostic testing that should be performed on patient specimens, physicians can go to 
http://www.cdc.gov/hai/outbreaks/meningitis.html. State health departments should be informed of 
patients undergoing evaluation. Clinicians should report any suspected adverse events following use of 
these products to FDA's MedWatch program at 1-800-332-1088 or www.fda.gov/medwatch.
*Case Definition
1: A  person with meningitis1 of sub-acute onset (1-4 weeks) following epidural injection after July 1, 2012.
2: A  person, who has not received a lumbar puncture, with basilar stroke 1-4 weeks following epidural injection after July 1, 20122.
3. A  person with evidence of spinal osteomyelitis or epidural abscess at the site of an epidural injection diagnosed 1-4 weeks after 
epidural injection after July 1, 2012.
1clinically diagnosed meningitis meaning 1 or more of the following symptoms: headache, fever, stiff neck, or photophobia and a 
CSF profile consistent with meningitis (elevated protein/low glucose/pleocytosis)
2These people, if possible, should have an LP.
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